LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Search

Inmode Ltd

Cerrado

SectorSanidad

13.74 1.63

Resumen

Variación precio

24h

Actual

Mínimo

13.52

Máximo

13.77

Métricas clave

By Trading Economics

Ingresos

5.2M

27M

Ventas

11M

104M

P/B

Media del Sector

9.392

57.833

BPA

0.38

Margen de beneficios

26.022

Empleados

660

EBITDA

5.7M

31M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+30.6% upside

Dividendos

By Dow Jones

Próximas Ganancias

27 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-175M

851M

Apertura anterior

12.11

Cierre anterior

13.74

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

144 / 350 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Inmode Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado
Ganancias
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Inmode Ltd previsión

Precio Objetivo

By TipRanks

30.6% repunte

Estimación a 12 Meses

Media 17.67 USD  30.6%

Máximo 21 USD

Mínimo 15 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Inmode Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.1 / 14.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

144 / 350 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat